The trajectory of companies tied to the drug's past presents a intricate investment landscape. While the initial success generated substantial gains, generic copies have significantly eroded revenue. Investing in related pharmaceutical businesses now requires a discerning assessment of intellectual property safeguards, evolving patient shifts , and